Optimization of Case Definitions for Sensitivity as a Preventive Strategy-A Modelling Exemplified with Rapid Diagnostic Test-Based Prevention of Sexual HIV Transmission.
HIV
RDT
human immunodeficiency virus
infectious disease
modelling
rapid diagnostic testing
sensitivity
symptoms
transmission prevention
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
10 Nov 2021
10 Nov 2021
Historique:
received:
11
10
2021
revised:
05
11
2021
accepted:
06
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
In clinical studies, case definitions are usually designed to optimally match the desired clinical state, because lacking specificity is associated with a risk of bias regarding the study outcome. In preventive medicine, however, high sensitivity is sometimes considered as more critical in order not to overlook infectious individuals, because the latter may be associated with ongoing spread of a transmittable disease. Accordingly, this work was focused on a theoretical model on how the sensitivity of case definitions can be optimized by adding clinical symptoms to diagnostic results for preventive purposes, if the associated reduction in specificity is considered as acceptable. The model was exemplified with an analysis on whether and in how far exposure risk can be reduced by the inclusion of observable symptoms during seroconversion syndrome in case of rapid diagnostic test-based prevention of sexual HIV transmission. The approach provided a high level of safety (negative predictive values close to 1) for the price of a considerably number of false positives (positive predictive values < 0.01 for some subpopulations). When applying such a sensitivity-optimized screening as a "diagnostics as prevention" strategy, the advantages of excellent negative predictive values need to be cautiously balanced against potential undesirable consequences of low positive predictive values.
Identifiants
pubmed: 34829425
pii: diagnostics11112079
doi: 10.3390/diagnostics11112079
pmc: PMC8620421
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Expert Rev Anti Infect Ther. 2015;13(10):1189-93
pubmed: 26359532
Trop Med Int Health. 2010 Mar;15(3):362-81
pubmed: 20409291
Emerg Infect Dis. 2018 Mar;24(3):413-416
pubmed: 29460740
BMC Public Health. 2020 Jul 20;20(1):1135
pubmed: 32689959
Epidemiol Infect. 2018 Jun;146(8):1015-1025
pubmed: 29655384
J Infect Dis. 2008 Sep 1;198(5):687-93
pubmed: 18662132
Rev Esp Quimioter. 2020 Dec;33(6):466-484
pubmed: 33070578
Lett Appl Microbiol. 2018 Oct;67(4):420-424
pubmed: 30074254
Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705
pubmed: 32845525
AIDS. 2014 Apr 24;28(7):1021-9
pubmed: 24691205
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):133-7
pubmed: 15905727
Clin Biochem Rev. 2008 Aug;29 Suppl 1:S83-7
pubmed: 18852864
Int J Environ Res Public Health. 2020 Jul 30;17(15):
pubmed: 32751507
Trop Med Int Health. 2020 Mar;25(3):357-363
pubmed: 31758838
Stud Fam Plann. 2008 Dec;39(4):321-34
pubmed: 19248718
PLoS One. 2016 Feb 18;11(2):e0149592
pubmed: 26891218
Future Microbiol. 2019 Nov;14:1465-1468
pubmed: 31904269
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
Emerg Infect Dis. 2016 Mar;22(3):532-4
pubmed: 26890854
Eur J Microbiol Immunol (Bp). 2018 May 05;8(2):47-52
pubmed: 29997911
Sex Transm Infect. 2001 Apr;77(2):84-92
pubmed: 11287683
Acta Trop. 2020 May;205:105377
pubmed: 32007448
Antibiotics (Basel). 2020 Jul 04;9(7):
pubmed: 32635553
Pan Afr Med J. 2020 Sep 15;37(Suppl 1):10
pubmed: 33294111
Lancet. 2008 Jul 26;372(9635):314-20
pubmed: 18657710
Am J Epidemiol. 1978 Jan;107(1):71-6
pubmed: 623091
Int Perspect Sex Reprod Health. 2013 Mar;39(1):14-21
pubmed: 23584464